TAVR does not worsen chronic kidney disease

Reuters Health - 17/09/2020 - Renal impairment may stay stable or even show improvement after transcatheter aortic-valve replacement (TAVR) in most patients with chronic kidney disease (CKD), according to an analysis of data from clinical trials. Poor baseline and post-operative renal function are risk factors for in-hospital and short- and intermediate-term mortality following TAVR, Dr. Robert J. Cubeddu of Cleveland Clinic Florida, in Weston, and colleagues note in the Journal of the American College of Cardiology. But it has been unclear what effect, if any, the procedure itself might have on renal impairment. To investigate, the researchers examined data on more than 5,000 patients with severe aortic stenosis who underwent TAVR between 2007 and 2014. At baseline, 91% had CKD of stage 2 or higher. Seven days after the procedure, CKD stage was either improved or unchanged in most of the 2,892 patients with data available on pre- and post-TAVR estimated glom...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 17 September, 202030 September, 2020